News coverage about Conatus Pharmaceuticals (NASDAQ:CNAT) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.1499363505014 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
- Non-Alcoholic Steatohepatitis 2017 Progress Update – Nasdaq (nasdaq.com)
- $12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter (americanbankingnews.com)
- Eye-Catching Shares: Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) – The Investor Guide (wallstreetnews24.com)
- Analysts recommend to Buy Healthcare Stock: Conatus Pharmaceuticals Inc. (CNAT) – Street Observer (press release) (streetobserver.com)
- Conatus Pharmaceuticals Inc. (CNAT)- Delight your Morning with Active Stocks – NASDAQ Times (nasdaqtimes.com)
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $9.33 million. During the same quarter in the previous year, the company earned ($0.30) EPS.
A number of research analysts have issued reports on the company. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Seaport Global Securities reiterated a “buy” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Finally, Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $16.17.
COPYRIGHT VIOLATION WARNING: This piece was published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.truebluetribune.com/2017/10/13/conatus-pharmaceuticals-cnat-earning-somewhat-positive-media-coverage-analysis-finds.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.